Mucopolysaccharidosis type II: Enzyme Replacement Therapy Efficiency
Mucopolysaccharidosis type II (MPS II), or Hunter syndrome, is the hereditary lysosomal storage disease caused by pathological variants in IDS gene. Such variants lead to iduronate-2-sulfatase enzyme deficiency and glycosaminoglycan catabolism disorder. Major clinical signs are central nervous syste...
Saved in:
Main Authors: | Nato D. Vashakmadze, Leyla S. Namazova-Baranova, Natalia V. Zhurkova, Ekaterina Yu. Zakharova, Grigory V. Revunenkov, Tina V. Lobjanidze, Marina A. Babaikina |
---|---|
Format: | Article |
Language: | English |
Published: |
"Paediatrician" Publishers LLC
2020-02-01
|
Series: | Вопросы современной педиатрии |
Subjects: | |
Online Access: | https://vsp.spr-journal.ru/jour/article/view/2264 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Allergic Reactions at Enzyme Replacement Therapy in Children with Mucopolysaccharidosis Type II
by: Julia G. Levina, et al.
Published: (2021-12-01) -
Non-Neuropathic Form of Mucopolysaccharidosis Type II: Clinical Cases
by: Nato D. Vashakmadze, et al.
Published: (2021-03-01) -
EFFICACY AND SAFETY OF ENZYME REPLACEMENT THERAPY IN CHILDREN WITH MUCOPOLYSACCHARIDOSIS TYPE I, II, AND VI: A SINGLE-CENTER COHORT STUDY
by: Liliia A. Osipova, et al.
Published: (2018-04-01) -
Enzyme Replacement Therapy with Idursulfase in Patients with Mucopolysaccharidosis Type II: Literature Review
by: Nato D. Vashakmadze, et al.
Published: (2021-12-01) -
Clinical Case of Drug Allergy to Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II
by: Julia G. Levina, et al.
Published: (2022-07-01)